



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>7</sup> :  G01N 33/68		A1	(11) International Publication Number: WO 00/52476
			(43) International Publication Date: 8 September 2000 (08.09.00)
<p>(21) International Application Number: PCT/CA00/00182</p> <p>(22) International Filing Date: 22 February 2000 (22.02.00)</p> <p>(30) Priority Data: 2,263,063 26 February 1999 (26.02.99) CA</p> <p>(71) Applicant (<i>for all designated States except US</i>): SKYE PHARMATECH INCORPORATED [CA/CA]; 6354 Viscount Road, Mississauga, Ontario L4V 1H3 (CA).</p> <p>(72) Inventor; and</p> <p>(75) Inventor/Applicant (<i>for US only</i>): JACKOWSKI, George [CA/CA]; 17725 Keele Street, Kettleby, Ontario L0G 1J0 (CA).</p> <p>(74) Agents: HOULE, Guy, J. et al.; Swabey Ogilvy Renault, Suite 1600, 1981 McGill College Avenue, Montréal, Québec H3A 2Y3 (CA).</p>		<p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report.</i></p>	
<p>(54) Title: METHOD FOR DIAGNOSING AND DISTINGUISHING STROKE</p> <pre> graph TD     A[CLINICAL SIGNS SUGGESTING STROKE] --&gt; B[1st BLOOD SAMPLE AT TIME OF PRESENTATION (ZERO TIME) MEASURE S100, NSE, MBP, AND Tm]     B --&gt; C[ALL MARKERS IN NORMAL RANGE]     C --&gt; D[FUNCTIONAL STROKE]     C --&gt; E[BRAIN INJURY]     C --&gt; F[ELEVATED LEVEL ANY MARKER POSITIVE]     D --&gt; G[SUSPECTED TIA]     D --&gt; H[SUSPECTED LACUNAR STROKE]     E --&gt; I[IF Tm ELEVATED WITH OR WITHOUT OTHER MARKERS]     E --&gt; J[IF EXTREMELY ELEVATED MBP (&gt;2000) WITH OR WITHOUT OTHER MARKERS]     E --&gt; K[S100 ALONE OR ALONG WITH ANY OTHER MARKER (NSE, MBP, Tm)]     E --&gt; L[ELEVATED S100, NSE, NORMAL MBP AND Tm]     F --&gt; M[SUSPECTED INTRACEREBRAL HEMORRHAGE]     F --&gt; N[SUSPECTED CEREBRAL INFARCT]     F --&gt; O[SUSPECTED SUBARACHNOID HEMORRHAGE]     G --&gt; P[ONLY NSE ELEVATED]     G --&gt; Q[NSE ALONG WITH OTHER MARKERS (S100, MBP, Tm)]     H --&gt; R[ONLY Tm ELEVATED]     H --&gt; S[Tm WITH OTHER MARKERS ELEVATED]     I --&gt; T[EXTREMELY ELEVATED MBP WITH OR WITHOUT OTHER MARKERS]     J --&gt; U[S100 WITH INCREASING NSE AND NORMAL LEVEL OF Tm]     K --&gt; V[S100 ALONE OR ALONG WITH INCREASING NSE OR Tm]     L --&gt; W[S100 WITH SIGNIFICANTLY ELEVATED MBP]     L --&gt; X[ELEVATED S100 AND NSE, NORMAL MBP AND Tm]     M --&gt; Y[LACUNAR INFARCT]     M --&gt; Z[INTRACEREBRAL HEMORRHAGE]     M --&gt; A1[EVOLVING CEREBRAL INFARCT]     N --&gt; A2[EVOLVING CEREBRAL INFARCT]     O --&gt; A3[SEVERE CEREBRAL EDEMA]     O --&gt; A4[EVOLVING CEREBRAL INFARCT]     P --&gt; A5[POOR CANDIDATE FOR THROMBOLYSIS]     Q --&gt; A6[GOOD CANDIDATE FOR THROMBOLYSIS]     R --&gt; A7[NORMAL LEVEL OF Tm]     S --&gt; A8[POOR CANDIDATE FOR THROMBOLYSIS]     T --&gt; A9[POOR CANDIDATE FOR THROMBOLYSIS]     U --&gt; A10[GOOD CANDIDATE FOR THROMBOLYSIS]     V --&gt; A11[EVOLVING CEREBRAL INFARCT]     W --&gt; A12[SEVERE CEREBRAL EDEMA]     X --&gt; A13[SUBARACHNOID HEMORRHAGE]     A1 --&gt; A14[ELEVATED Tm]     A1 --&gt; A15[NORMAL LEVEL OF Tm]     A2 --&gt; A16[EVOLVING CEREBRAL INFARCT]     A3 --&gt; A17[EVOLVING CEREBRAL INFARCT]     A4 --&gt; A18[EVOLVING CEREBRAL INFARCT]     A5 --&gt; A19[POOR CANDIDATE FOR THROMBOLYSIS]     A6 --&gt; A20[GOOD CANDIDATE FOR THROMBOLYSIS]     A7 --&gt; A21[POOR CANDIDATE FOR THROMBOLYSIS]     A8 --&gt; A22[POOR CANDIDATE FOR THROMBOLYSIS]     A9 --&gt; A23[GOOD CANDIDATE FOR THROMBOLYSIS]     A10 --&gt; A24[EVOLVING CEREBRAL INFARCT]     A11 --&gt; A25[EVOLVING CEREBRAL INFARCT]     A12 --&gt; A26[SEVERE CEREBRAL EDEMA]     A13 --&gt; A27[SUBARACHNOID HEMORRHAGE]     A14 --&gt; A28[POOR CANDIDATE FOR THROMBOLYSIS]     A15 --&gt; A29[GOOD CANDIDATE FOR THROMBOLYSIS]     A16 --&gt; A30[EVOLVING CEREBRAL INFARCT]     A17 --&gt; A31[EVOLVING CEREBRAL INFARCT]     A18 --&gt; A32[EVOLVING CEREBRAL INFARCT]     A20 --&gt; A33[EVOLVING CEREBRAL INFARCT]     A23 --&gt; A34[EVOLVING CEREBRAL INFARCT]     A25 --&gt; A35[EVOLVING CEREBRAL INFARCT]     A27 --&gt; A36[SEVERE CEREBRAL EDEMA]     A29 --&gt; A37[SUBARACHNOID HEMORRHAGE]     A30 --&gt; A38[EVOLVING CEREBRAL INFARCT]     A31 --&gt; A39[EVOLVING CEREBRAL INFARCT]     A32 --&gt; A40[EVOLVING CEREBRAL INFARCT]     A33 --&gt; A41[EVOLVING CEREBRAL INFARCT]     A34 --&gt; A42[EVOLVING CEREBRAL INFARCT]     A35 --&gt; A43[EVOLVING CEREBRAL INFARCT]     A36 --&gt; A44[SEVERE CEREBRAL EDEMA]     A37 --&gt; A45[SUBARACHNOID HEMORRHAGE]     A38 --&gt; A46[EVOLVING CEREBRAL INFARCT]     A39 --&gt; A47[EVOLVING CEREBRAL INFARCT]     A40 --&gt; A48[EVOLVING CEREBRAL INFARCT]     A41 --&gt; A49[EVOLVING CEREBRAL INFARCT]     A42 --&gt; A50[EVOLVING CEREBRAL INFARCT]     A43 --&gt; A51[EVOLVING CEREBRAL INFARCT]     A44 --&gt; A52[SEVERE CEREBRAL EDEMA]     A45 --&gt; A53[SUBARACHNOID HEMORRHAGE]     A46 --&gt; A54[EVOLVING CEREBRAL INFARCT]     A47 --&gt; A55[EVOLVING CEREBRAL INFARCT]     A48 --&gt; A56[EVOLVING CEREBRAL INFARCT]     A49 --&gt; A57[EVOLVING CEREBRAL INFARCT]     A50 --&gt; A58[EVOLVING CEREBRAL INFARCT]     A51 --&gt; A59[EVOLVING CEREBRAL INFARCT]     A52 --&gt; A60[EVOLVING CEREBRAL INFARCT]     A53 --&gt; A61[EVOLVING CEREBRAL INFARCT]     A54 --&gt; A62[SEVERE CEREBRAL EDEMA]     A55 --&gt; A63[SUBARACHNOID HEMORRHAGE]     A56 --&gt; A64[EVOLVING CEREBRAL INFARCT]     A57 --&gt; A65[EVOLVING CEREBRAL INFARCT]     A58 --&gt; A66[EVOLVING CEREBRAL INFARCT]     A59 --&gt; A67[EVOLVING CEREBRAL INFARCT]     A60 --&gt; A68[EVOLVING CEREBRAL INFARCT]     A61 --&gt; A69[EVOLVING CEREBRAL INFARCT]     A62 --&gt; A70[EVOLVING CEREBRAL INFARCT]     A63 --&gt; A71[EVOLVING CEREBRAL INFARCT]     A64 --&gt; A72[SEVERE CEREBRAL EDEMA]     A65 --&gt; A73[SUBARACHNOID HEMORRHAGE]     A66 --&gt; A74[EVOLVING CEREBRAL INFARCT]     A67 --&gt; A75[EVOLVING CEREBRAL INFARCT]     A68 --&gt; A76[EVOLVING CEREBRAL INFARCT]     A69 --&gt; A77[EVOLVING CEREBRAL INFARCT]     A70 --&gt; A78[EVOLVING CEREBRAL INFARCT]     A71 --&gt; A79[EVOLVING CEREBRAL INFARCT]     A72 --&gt; A80[EVOLVING CEREBRAL INFARCT]     A73 --&gt; A81[EVOLVING CEREBRAL INFARCT]     A74 --&gt; A82[SEVERE CEREBRAL EDEMA]     A75 --&gt; A83[SUBARACHNOID HEMORRHAGE]     A76 --&gt; A84[EVOLVING CEREBRAL INFARCT]     A77 --&gt; A85[EVOLVING CEREBRAL INFARCT]     A78 --&gt; A86[EVOLVING CEREBRAL INFARCT]     A79 --&gt; A87[EVOLVING CEREBRAL INFARCT]     A80 --&gt; A88[EVOLVING CEREBRAL INFARCT]     A81 --&gt; A89[EVOLVING CEREBRAL INFARCT]     A82 --&gt; A90[EVOLVING CEREBRAL INFARCT]     A83 --&gt; A91[EVOLVING CEREBRAL INFARCT]     A84 --&gt; A92[SEVERE CEREBRAL EDEMA]     A85 --&gt; A93[SUBARACHNOID HEMORRHAGE]     A86 --&gt; A94[EVOLVING CEREBRAL INFARCT]     A87 --&gt; A95[EVOLVING CEREBRAL INFARCT]     A88 --&gt; A96[EVOLVING CEREBRAL INFARCT]     A89 --&gt; A97[EVOLVING CEREBRAL INFARCT]     A90 --&gt; A98[EVOLVING CEREBRAL INFARCT]     A91 --&gt; A99[EVOLVING CEREBRAL INFARCT]     A92 --&gt; A100[EVOLVING CEREBRAL INFARCT]     A93 --&gt; A101[EVOLVING CEREBRAL INFARCT]     A94 --&gt; A102[SEVERE CEREBRAL EDEMA]     A95 --&gt; A103[SUBARACHNOID HEMORRHAGE]     A96 --&gt; A104[EVOLVING CEREBRAL INFARCT]     A97 --&gt; A105[EVOLVING CEREBRAL INFARCT]     A98 --&gt; A106[EVOLVING CEREBRAL INFARCT]     A99 --&gt; A107[EVOLVING CEREBRAL INFARCT]     A100 --&gt; A108[EVOLVING CEREBRAL INFARCT]     A101 --&gt; A109[EVOLVING CEREBRAL INFARCT]     A102 --&gt; A110[EVOLVING CEREBRAL INFARCT]     A103 --&gt; A111[EVOLVING CEREBRAL INFARCT]     A104 --&gt; A112[SEVERE CEREBRAL EDEMA]     A105 --&gt; A113[SUBARACHNOID HEMORRHAGE]     A106 --&gt; A114[EVOLVING CEREBRAL INFARCT]     A107 --&gt; A115[EVOLVING CEREBRAL INFARCT]     A108 --&gt; A116[EVOLVING CEREBRAL INFARCT]     A109 --&gt; A117[EVOLVING CEREBRAL INFARCT]     A110 --&gt; A118[EVOLVING CEREBRAL INFARCT]     A111 --&gt; A119[EVOLVING CEREBRAL INFARCT]     A112 --&gt; A120[EVOLVING CEREBRAL INFARCT]     A113 --&gt; A121[EVOLVING CEREBRAL INFARCT]     A114 --&gt; A122[SEVERE CEREBRAL EDEMA]     A115 --&gt; A123[SUBARACHNOID HEMORRHAGE]     A116 --&gt; A124[EVOLVING CEREBRAL INFARCT]     A117 --&gt; A125[EVOLVING CEREBRAL INFARCT]     A118 --&gt; A126[EVOLVING CEREBRAL INFARCT]     A119 --&gt; A127[EVOLVING CEREBRAL INFARCT]     A120 --&gt; A128[EVOLVING CEREBRAL INFARCT]     A121 --&gt; A129[EVOLVING CEREBRAL INFARCT]     A122 --&gt; A130[EVOLVING CEREBRAL INFARCT]     A123 --&gt; A131[EVOLVING CEREBRAL INFARCT]     A124 --&gt; A132[SEVERE CEREBRAL EDEMA]     A125 --&gt; A133[SUBARACHNOID HEMORRHAGE]     A126 --&gt; A134[EVOLVING CEREBRAL INFARCT]     A127 --&gt; A135[EVOLVING CEREBRAL INFARCT]     A128 --&gt; A136[EVOLVING CEREBRAL INFARCT]     A129 --&gt; A137[EVOLVING CEREBRAL INFARCT]     A130 --&gt; A138[EVOLVING CEREBRAL INFARCT]     A131 --&gt; A139[EVOLVING CEREBRAL INFARCT]     A132 --&gt; A140[EVOLVING CEREBRAL INFARCT]     A133 --&gt; A141[SEVERE CEREBRAL EDEMA]     A134 --&gt; A142[SUBARACHNOID HEMORRHAGE]     A135 --&gt; A143[EVOLVING CEREBRAL INFARCT]     A136 --&gt; A144[EVOLVING CEREBRAL INFARCT]     A137 --&gt; A145[EVOLVING CEREBRAL INFARCT]     A138 --&gt; A146[EVOLVING CEREBRAL INFARCT]     A139 --&gt; A147[EVOLVING CEREBRAL INFARCT]     A140 --&gt; A148[EVOLVING CEREBRAL INFARCT]     A141 --&gt; A149[SEVERE CEREBRAL EDEMA]     A142 --&gt; A150[SUBARACHNOID HEMORRHAGE]     A143 --&gt; A151[EVOLVING CEREBRAL INFARCT]     A144 --&gt; A152[EVOLVING CEREBRAL INFARCT]     A145 --&gt; A153[EVOLVING CEREBRAL INFARCT]     A146 --&gt; A154[EVOLVING CEREBRAL INFARCT]     A147 --&gt; A155[EVOLVING CEREBRAL INFARCT]     A148 --&gt; A156[EVOLVING CEREBRAL INFARCT]     A149 --&gt; A157[SEVERE CEREBRAL EDEMA]     A150 --&gt; A158[SUBARACHNOID HEMORRHAGE]     A151 --&gt; A159[EVOLVING CEREBRAL INFARCT]     A152 --&gt; A160[EVOLVING CEREBRAL INFARCT]     A153 --&gt; A161[EVOLVING CEREBRAL INFARCT]     A154 --&gt; A162[EVOLVING CEREBRAL INFARCT]     A155 --&gt; A163[EVOLVING CEREBRAL INFARCT]     A156 --&gt; A164[EVOLVING CEREBRAL INFARCT]     A157 --&gt; A165[SEVERE CEREBRAL EDEMA]     A158 --&gt; A166[SUBARACHNOID HEMORRHAGE]     A159 --&gt; A167[EVOLVING CEREBRAL INFARCT]     A160 --&gt; A168[EVOLVING CEREBRAL INFARCT]     A161 --&gt; A169[EVOLVING CEREBRAL INFARCT]     A162 --&gt; A170[EVOLVING CEREBRAL INFARCT]     A163 --&gt; A171[EVOLVING CEREBRAL INFARCT]     A164 --&gt; A172[SEVERE CEREBRAL EDEMA]     A165 --&gt; A173[SUBARACHNOID HEMORRHAGE]     A166 --&gt; A174[EVOLVING CEREBRAL INFARCT]     A167 --&gt; A175[EVOLVING CEREBRAL INFARCT]     A168 --&gt; A176[EVOLVING CEREBRAL INFARCT]     A169 --&gt; A177[EVOLVING CEREBRAL INFARCT]     A170 --&gt; A178[EVOLVING CEREBRAL INFARCT]     A171 --&gt; A179[EVOLVING CEREBRAL INFARCT]     A172 --&gt; A180[SEVERE CEREBRAL EDEMA]     A173 --&gt; A181[SUBARACHNOID HEMORRHAGE]     A174 --&gt; A182[EVOLVING CEREBRAL INFARCT]     A175 --&gt; A183[EVOLVING CEREBRAL INFARCT]     A176 --&gt; A184[EVOLVING CEREBRAL INFARCT]     A177 --&gt; A185[EVOLVING CEREBRAL INFARCT]     A178 --&gt; A186[EVOLVING CEREBRAL INFARCT]     A179 --&gt; A187[EVOLVING CEREBRAL INFARCT]     A180 --&gt; A188[SEVERE CEREBRAL EDEMA]     A181 --&gt; A189[SUBARACHNOID HEMORRHAGE]     A182 --&gt; A190[EVOLVING CEREBRAL INFARCT]     A183 --&gt; A191[EVOLVING CEREBRAL INFARCT]     A184 --&gt; A192[EVOLVING CEREBRAL INFARCT]     A185 --&gt; A193[EVOLVING CEREBRAL INFARCT]     A186 --&gt; A194[EVOLVING CEREBRAL INFARCT]     A187 --&gt; A195[EVOLVING CEREBRAL INFARCT]     A188 --&gt; A196[SEVERE CEREBRAL EDEMA]     A189 --&gt; A197[SUBARACHNOID HEMORRHAGE]     A190 --&gt; A198[EVOLVING CEREBRAL INFARCT]     A191 --&gt; A199[EVOLVING CEREBRAL INFARCT]     A192 --&gt; A200[EVOLVING CEREBRAL INFARCT]     A193 --&gt; A201[EVOLVING CEREBRAL INFARCT]     A194 --&gt; A202[EVOLVING CEREBRAL INFARCT]     A195 --&gt; A203[EVOLVING CEREBRAL INFARCT]     A196 --&gt; A204[SEVERE CEREBRAL EDEMA]     A197 --&gt; A205[SUBARACHNOID HEMORRHAGE]     A198 --&gt; A206[EVOLVING CEREBRAL INFARCT]     A199 --&gt; A207[EVOLVING CEREBRAL INFARCT]     A200 --&gt; A208[EVOLVING CEREBRAL INFARCT]     A201 --&gt; A209[EVOLVING CEREBRAL INFARCT]     A202 --&gt; A210[EVOLVING CEREBRAL INFARCT]     A203 --&gt; A211[SEVERE CEREBRAL EDEMA]     A204 --&gt; A212[SUBARACHNOID HEMORRHAGE]     A205 --&gt; A213[EVOLVING CEREBRAL INFARCT]     A206 --&gt; A214[EVOLVING CEREBRAL INFARCT]     A207 --&gt; A215[EVOLVING CEREBRAL INFARCT]     A208 --&gt; A216[EVOLVING CEREBRAL INFARCT]     A209 --&gt; A217[EVOLVING CEREBRAL INFARCT]     A210 --&gt; A218[EVOLVING CEREBRAL INFARCT]     A211 --&gt; A219[SEVERE CEREBRAL EDEMA]     A212 --&gt; A220[SUBARACHNOID HEMORRHAGE]     A213 --&gt; A221[EVOLVING CEREBRAL INFARCT]     A214 --&gt; A222[EVOLVING CEREBRAL INFARCT]     A215 --&gt; A223[EVOLVING CEREBRAL INFARCT]     A216 --&gt; A224[EVOLVING CEREBRAL INFARCT]     A217 --&gt; A225[EVOLVING CEREBRAL INFARCT]     A218 --&gt; A226[SEVERE CEREBRAL EDEMA]     A219 --&gt; A227[SUBARACHNOID HEMORRHAGE]     A220 --&gt; A228[EVOLVING CEREBRAL INFARCT]     A221 --&gt; A229[EVOLVING CEREBRAL INFARCT]     A222 --&gt; A230[EVOLVING CEREBRAL INFARCT]     A223 --&gt; A231[EVOLVING CEREBRAL INFARCT]     A224 --&gt; A232[EVOLVING CEREBRAL INFARCT]     A225 --&gt; A233[SEVERE CEREBRAL EDEMA]     A226 --&gt; A234[SUBARACHNOID HEMORRHAGE]     A227 --&gt; A235[EVOLVING CEREBRAL INFARCT]     A228 --&gt; A236[EVOLVING CEREBRAL INFARCT]     A229 --&gt; A237[EVOLVING CEREBRAL INFARCT]     A230 --&gt; A238[EVOLVING CEREBRAL INFARCT]     A231 --&gt; A239[EVOLVING CEREBRAL INFARCT]     A232 --&gt; A240[SEVERE CEREBRAL EDEMA]     A233 --&gt; A241[SUBARACHNOID HEMORRHAGE]     A234 --&gt; A242[EVOLVING CEREBRAL INFARCT]     A235 --&gt; A243[EVOLVING CEREBRAL INFARCT]     A236 --&gt; A244[EVOLVING CEREBRAL INFARCT]     A237 --&gt; A245[EVOLVING CEREBRAL INFARCT]     A238 --&gt; A246[EVOLVING CEREBRAL INFARCT]     A239 --&gt; A247[EVOLVING CEREBRAL INFARCT]     A240 --&gt; A248[SEVERE CEREBRAL EDEMA]     A241 --&gt; A249[SUBARACHNOID HEMORRHAGE]     A242 --&gt; A250[EVOLVING CEREBRAL INFARCT]     A243 --&gt; A251[EVOLVING CEREBRAL INFARCT]     A244 --&gt; A252[EVOLVING CEREBRAL INFARCT]     A245 --&gt; A253[EVOLVING CEREBRAL INFARCT]     A246 --&gt; A254[EVOLVING CEREBRAL INFARCT]     A247 --&gt; A255[EVOLVING CEREBRAL INFARCT]     A248 --&gt; A256[SEVERE CEREBRAL EDEMA]     A249 --&gt; A257[SUBARACHNOID HEMORRHAGE]     A250 --&gt; A</pre>			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon			PT	Portugal		
CN	China	KR	Republic of Korea	RO	Romania		
CU	Cuba	KZ	Kazakhstan	RU	Russian Federation		
CZ	Czech Republic	LC	Saint Lucia	SD	Sudan		
DE	Germany	LI	Liechtenstein	SE	Sweden		
DK	Denmark	LK	Sri Lanka	SG	Singapore		
EE	Estonia	LR	Liberia				

## METHOD FOR DIAGNOSING AND DISTINGUISHING STROKE

### BACKGROUND OF THE INVENTION

5        This application is directed to a method for diagnosing whether a subject has had a stroke and, if so, differentiating between the different types of stroke. More specifically, the method includes analyzing the subject's body fluid for at least four selected markers of stroke. There are also described diagnostic devices and kits for use in the method.

10      The impact of stroke on the health of human beings is very great when considered in terms of mortality and even more devastating when disability is considered. For example, stroke is the third leading cause of death in adults in the United States, after ischemic heart disease and all forms of cancer. For people who survive, stroke is the leading cause of disability. The direct medical costs due to 15     stroke and the cost of lost employment amount to billions of dollars annually. Approximately 85% of all strokes are ischemic (thrombotic and embolic) with the remainder being hemorrhagic.

20      Stroke is an underserved market for both therapeutics and diagnostic techniques. In the United States alone over 700,000 people have strokes each year. A multiple of that number would be suspected of having strokes with diagnostics only confirmed by expensive technology including computer-assisted tomography (CAT) scans and magnetic resonance imaging (MRI). However, these sophisticated technologies are not available in all hospitals and they are also not sensitive enough to diagnose ischemic stroke at an early stage.

25      Stroke is a clinical diagnosis made by a neurologist, usually as a consultation. Current methods for diagnosing stroke include symptom evaluation, medical history, chest X-ray, ECG (electrical heart activity), EEG (brain nerve cell activity), CAT scan to assess brain damage and MRI to obtain internal body visuals. A number of blood tests may be performed to search for internal bleeding. These include complete blood

count, prothrombin time, partial thromboplastin time, serum electrolytes and blood glucose.

Determining the immediate cause of a stroke can be difficult especially upon presentation where the diagnosis relies mainly on imaging techniques.

5     Approximately 50% of cerebral infarctions are not visible on a CAT scan. Further, even though a CAT scan can be very sensitive for the identification of hemorrhagic stroke, it is not very sensitive for cerebral ischemia during evaluation of stroke and is usually positive at from 24 to 36 hours after onset of stroke. As a result a window of opportunity for rapid treatment would usually have expired once the current

10    diagnostic techniques positively identify a stroke.

The treatment of stroke includes preventive therapies such as antihypertensive and antiplatelet drugs which control and reduce blood pressure and thus reduce the likelihood of stroke. Also, the development of thrombolytic drugs such as t-PA (tissue plasminogen activator) has provided a significant advance in the treatment of

15    ischemic stroke victims but to be effective and minimize damage from acute stroke it is necessary to begin treatment very early, for example, within about three hours after the onset of symptoms. These drugs dissolve blood vessel clots which block blood flow to the brain and which are the cause of approximately 80% of strokes. However, these drugs can also present the side effect of increased risk of bleeding. Various

20    neuroprotectors such as calcium channel antagonist can stop damage to the brain as a result of ischemic insult. The window of treatment for these drugs is typically broader than that for the clot dissolvers and they do not increase the risk of bleeding.

Diagnostic techniques for the early diagnosis of stroke and identification of the type of stroke are needed to allow the physician to prescribe the appropriate

25    therapeutic drugs at an early stage in the cerebral event. Various markers for stroke are known and analytical techniques for the determination of such markers have been described in the art. As used herein the term "marker" refers to a protein or other molecule that is released from the brain during a cerebral ischemic or hemorrhagic event. Such markers include isoforms of proteins that are unique to the brain.

30     It has been reported in the literature that myelin basic protein (MBP) concentration, in cerebrospinal fluid (CSF) increases after sufficient damage to

neuronal tissue, head trauma and AIDS dementia. Further, it has been reported that ultrastructural immunocytochemistry studies using anti-MBP antibodies have shown that MBP is localized exclusively in the myelin sheath. Thus, it has been suggested the MBP levels in CSF or serum be used as a marker of cerebral damage in acute cerebrovascular disease. See Strand, T., et al., Brain and plasma proteins in spinal fluid as markers for brain damage and severity of stroke, *Stroke* (1984) 15; 138-144. The increase in MBP concentration in CSF is most evident in about four to five days after the onset of thrombotic stroke while in cerebral hemorrhage the increase was highest almost immediately after onset. See Garcia-Alex, A., et al., Neuron-specific enolase and myelin basic protein: Relationship of cerebrospinal fluid concentration to the neurologic condition of asphyxiated full-term infants, *Pediatrics* (1994) 93; 234-240. It has also been found that patients with transitory ischemic attack (TIA) had normal CSF values for MBP while those with cerebral infarction and hemorrhage had elevated values. In cerebral infarction there was a significant increase in MBP concentration in CSF from the first to second lumbar puncture while patients with intracerebral hemorrhage had reached already markedly elevated levels at the first lumbar puncture. It was reported that the kinetic difference in MBP release may be useful in the differential diagnosis of hemorrhagic and ischemic stroke. MBP levels in CSF also correlated to the visibility of the cerebral lesion at CT scan and to the short-term outcome of the patients. Further, the concentration of MBP increased with the extent of brain lesion and high values indicated a poor short-term prognosis for the patient. See Strand, T. et al, previously cited.

S100 protein is another marker which may be taken as a useful marker for assessing neurologic damage and for determining the extent of brain damage and for determining the extent of brain lesions. Thus, it has been suggested for use as an aid in the diagnosis and assessment of brain lesions and neurological damage due to stroke. See Missler, U., Weismann, M., Friedrich, C. and Kaps, M., S100 protein and neuron-specific enolase concentrations in blood as indicators of infarction volume and prognosis in acute ischemic stroke, *Stroke* (1997) 28; 1956-60.

Neuron-specific enolase (NSE) also has been suggested as a useful marker of neurologic damage in the study of stroke with particular application in the assessment

of treatment. See Teasdale, G. and Jennett, B., Assessment of coma and impaired consciousness, Lancet (1974) 2; 81-84.

There continues to be a need for diagnostic techniques which can provide timely information concerning the type of stroke suffered by a patient, the onset of occurrence, the location of the event, the identification of appropriate patients who will benefit from treatment with the appropriate drug and the identification of patients who are at risk of bleeding as a result of treatment. Such techniques can provide data which will allow a physician to determine quickly the appropriate treatment required by the patient and permit early intervention.

It is therefore an object of this invention to provide a method for rapidly diagnosing and distinguishing stroke.

It is a further object of the invention to provide a method for distinguishing between thrombotic strokes and hemorrhagic strokes.

It is another object of the invention to provide such a method which includes analyzing the body fluid of a patient for at least four markers of stroke.

It is yet another object to provide a method which can provide information relating to the time of onset of the stroke.

It is still another object to provide diagnostic assay devices for use in the method.

20

#### SUMMARY OF THE INVENTION

These and other objects and advantages are accomplished in accordance with the invention by providing a method that is capable of determining whether a patient has suffered a stroke and, if so, whether the event is thrombotic or hemorrhagic. According to the method, a body fluid of the patient is analyzed for four molecules which are cell type specific, three of which are specific ischemic markers, namely S100 protein, myelin basic protein (MBP) and specific neuronal enolase (NSE) and one brain endothelial membrane protein, for example, thrombomodulin (Tm). The method analyzes the isoforms of the marker proteins which are specific to the brain.

The analyses of these markers may be carried out on the same sample of body fluid or on multiple samples of body fluid. In the latter embodiment the different body fluid samples may be taken at the same time or at different time periods.

The information which is obtained according to the method of the invention can be provided at the critically important early stages of a stroke, e.g., within the first three to six hours after onset of symptoms since the analysis of the patient's body fluid can be carried out in about 45 to 50 minutes after the body fluid is collected. The data can be vital to the physician by assisting in the determination of how to treat a patient presenting with symptoms of stroke or suspected of having a stroke. The data can rule stroke in or out, and differentiate between ischemic and hemorrhagic stroke and therefore exclude hemorrhagic stroke patients from being given clot dissolving therapeutics because of the risk of increased bleeding. The data can also identify patients who are at risk of bleeding as a result of treatment, i.e., patients with compromised brain vasculature. Further, the method can provide at an early stage prognostic information relating to the outcome of intervention which can improve patient selection for appropriate therapeutics and intervention. The method of the invention is diagnostic well before the imaging technologies. In addition, these data can indicate the location of the stroke within the brain and the extent of damage to the brain as well as determine whether the extent of the stroke is increasing. The cerebral infarct associated with stroke, made up of dead and dying brain tissue, which forms because of inadequate oxygenation typically increases in size during the acute period after ischemia begins. By measuring the markers in samples of body fluid taken at different points in time the progress of the stroke can be ascertained.

#### BRIEF DESCRIPTION OF THE DRAWINGS

The invention will now be described further in detail with respect to various preferred embodiments thereof in conjunction with the accompanying drawings wherein:

Fig. 1 is a graphical illustration of the concentration over time (in minutes) of two marker proteins which are indicative of cerebral condition or status;

Fig. 2 is a flow chart illustrating how data obtained according to an embodiment of the invention can be used for the diagnosis of cerebral condition or status; and

5 Figs. 3-10 are graphical illustrations of the concentration over time (in days) of four marker proteins analyzed according to an embodiment of the invention.

#### DESCRIPTION OF THE PREFERRED EMBODIMENTS

The markers which are analyzed according to the method of the invention are released into the circulation and are present in the blood and other body fluids. Preferably blood, or any blood product that contains them such as, for example, 10 plasma, serum, cytolized blood (e.g., by treatment with hypotonic buffer or detergents), and dilutions and preparations thereof is analyzed according to the invention. In another preferred embodiment the concentration of the markers in CSF is measured.

15 The terms "above normal" and "above threshold" are used herein to refer to a level of a marker that is greater than the level of the marker observed in normal individuals, that is, individuals who are not undergoing a cerebral event, i.e. an injury to the brain which may be ischemic, mechanical or infectious. For some markers, no or infinitesimally low levels of the marker may be present normally in an individual's blood. For others of the markers analyzed for according to the invention, detectable 20 levels may be present normally in blood. Thus, these terms contemplate a level that is significantly above the normal level found in individuals. The term "significantly" refers to statistical significance and generally means a two standard deviation (SD) above normal, or higher, concentration of the marker is present. The assay method by which the analysis for any particular marker protein is carried out must be sufficiently 25 sensitive to be able to detect the level of the marker which is present over the concentration range of interest and also must be highly specific.

The four primary markers which are measured according to the present method are proteins which are released by the specific brain cells as the cells become damaged during a cerebral event. These proteins can be either in their native form or 30 immunologically detectable fragments of the proteins resulting, for example, by

enzyme activity from proteolytic breakdown. The specific four primary markers when mentioned in the present application, including the claims hereof, are intended to include fragments of the proteins which can be immunologically detected. By "immunologically detectable" is meant that the protein fragments contain an epitope which is specifically recognized by a cognate antibody.

As mentioned previously, the markers analyzed according to the method of the invention are cell type specific. Myelin basic protein (MBP) is a highly basic protein, localized in the myelin sheath, and accounts for about 30% of the total protein of the myelin in the human brain. The protein exists as a single polypeptide chain of 170 amino acid residues which has a rod-like structure with dimensions of  $1.5 \times 150$  nm and a molecular weight of about 18,500 Dalton. It is a flexible protein which exists in a random coil devoid of  $\alpha$  helices  $\beta$  conformations.

The increase of MBP concentration in blood and CSF is most evident about four to five days after the onset of ischemic stroke while in cerebral hemorrhage the increase is highest almost immediately after the onset. Further, patients with TIA have normal values for MBP while those with cerebral infarction and intracerebral hemorrhage have elevated values. A normal value for a person who has not had a cerebral event is from 0.00 to about 0.016 ng/mL. MBP has a half-life in serum of about one hour and is a sensitive marker for cerebral hemorrhage.

The S100 protein is a cytoplasmic acidic calcium binding protein found predominantly in the gray matter of the brain, primarily in glia and Schwann cells. The protein exists in several homo- or heterodimeric isoforms consisting of two immunologically distinct subunits, alpha (MW = 10,400 Dalton) and beta (MW = 10,500 Dalton) while the S100 $\alpha\sigma$  is the homodimer  $\alpha\alpha$  which is found mainly in striated muscle, heart and kidney. The S100 $b$  isoform is the 21,000 Dalton homodimer  $\beta\beta$ . It is present in high concentration in glial cells and Schwann cells and is thus tissue specific. It is released during acute damage to the central nervous system and is a sensitive marker for cerebral infarction. According to the method of the invention, the assay is specific for the  $\beta$ -subunit of the S100 protein.

The S100b isoform is a specific brain marker released during acute damage to the central nervous system. It is eliminated by the kidney and has a half-life of about two hours in human serum. Repeated measurements of S100 serum levels are useful to follow the course of neurologic damage. Additionally, the presence of elevated 5 S100 levels in CSF or serum, in association with stroke symptoms, can be useful in the differential diagnosis of stroke and may be a valuable indicator of cerebral infarction.

The enzyme enolase (EC 4.2.1.11) catalyzes the interconversion of 2-phosphoglycerate and phosphoenolpyruvate in the glycolytic pathway. The enzyme 10 exists in three isoproteins each the product of a separate gene. The gene loci have been designated ENO1, ENO2 and ENO3. The gene product of ENO1 is the nonneuronal enolase (NNE or  $\alpha$ ), which is widely distributed in various mammalian tissues. The gene product of ENO2 is the muscle specific enolase (MSE or  $\beta$ ) which is localized mainly in the cardiac and striated muscle, while the product of the ENO3 15 gene is the neuronal specific enolase (NSE or  $\gamma$ ) which is largely found in the neurons and neuroendocrine cells. The native enzymes are found as homo- or heterodimeric isoforms composed of three immunologically distinct subunits,  $\alpha$ ,  $\beta$  and  $\gamma$ . Each subunit has a molecular weight of approximately 39,000 Dalton.

The  $\alpha\gamma$  and  $\gamma\gamma$  enolase isoforms, which have been designated neuronal specific 20 enolase (NSE) each have a molecular weight of approximately 80,000 Dalton. It has been shown that NSE concentration in CSF increases after experimental focal ischemia and the release of NSE from damaged cerebral tissue into the CSF reflects the development and size of the infarcts. NSE has a serum half-life of about 48 hours and its peak concentration has been shown to occur later after cerebral artery (MCA) 25 occlusion. NSE levels in CSF have been found to be elevated in acute and/or extensive disorders including subarachnoid hemorrhage and acute cerebral infarction.

The fourth marker protein measured according to the invention is a brain endothelial membrane protein. Endothelial cells which line the small blood vessels of the brain possess a unique expression of cell surface, receptors, transporters and 30 intracellular enzymes that serve to tightly regulate exchange of solutes between blood

and brain parenchyma. Brain endothelial membrane proteins include: Thrombomodulin (Tm), a 105,000 Dalton surface glycoprotein involved in the regulation of intravascular coagulation; Glucose Transporter (Gluc 1), a 55,000 Dalton cell surface transmembrane protein which may exist in dimeric or tetrameric form; Neurothelin/HT7, a 43,000 Dalton protein integrated into the cytoplasmic membrane transport protein; Gamma Glutamyl Transpeptidase, a protein which is found as a heterodimeric isoform composed of 22,000 and 25,000 Dalton subunits and is involved in the transfer of gamma glutamyl residue from glutathione to amino acids; and P-glycoprotein, a multidrug resistant membrane spanning protein. In a preferred embodiment of the method Tm is the brain endothelial membrane protein which is measured. Tm is a sensitive marker for lacunar infarcts.

The data obtained according to the method indicate whether a stroke has occurred and, if so, the type of stroke, the localization of the damage and the spread of the damage. Where the levels of all four markers are negative, i.e., within the normal range, there is no cerebral injury. When only the brain endothelial membrane protein, e.g., Tm, is elevated, or positive, i.e., the level is at least 2SD above normal, the stroke is a lacunar infarct present in the basal ganglia and deep white matter of the brain. When the NSE level is positive and the S100 and/or MBP levels are negative (the brain endothelial membrane protein marker is positive or negative) the patient has suffered a TIA.

According to another preferred embodiment, a fifth marker, which is from the specific cell type of one of the three ischemic markers analyzed according to the method of the invention, is measured to provide information related to the time of onset of the stroke. It should be recognized that the onset of stroke symptoms is not always known, particularly if the patient is unconscious or elderly and a reliable clinical history is not always available. An indication of the time of onset of the stroke can be obtained by relying on the differing release kinetics of brain markers having different molecular weights. The time release of brain markers into the circulation following brain injury is dependent on the size of the marker, with smaller markers tending to be released earlier in the event while larger markers tend to be released later. Fig. 1 illustrates the release kinetics of two marker proteins which are

analyzed according to the method of the invention, namely MBP and S100. These data were obtained from fluid collected from the brain tissue of a pig after coronary bypass surgery was performed. The samples were collected at 0, 30, 120, 180 and 240 minutes after the subject had been removed from the bypass machine. The 5 concentration values are expressed in multiples of a baseline value which was the concentration at time zero. These data indicate that the release of MBP (MW = 18,500) appears to reach a maximum about 120 minutes after the ischemic event whereas the release of S100 (MW = 21,000) does so at after about 180 minutes. Thus, by measuring an additional protein marker from the specific cell type of one of 10 the three ischemic markers utilized in the method of the invention, data relating to the time of onset can be obtained. The time of onset is defined as the moment of onset of clinical symptoms of stroke. In this preferred embodiment the second marker protein is a larger, i.e., a higher molecular weight marker, than the primary marker of the same cell type.

15 The three ischemic markers utilized according to the invention and various other high molecular weight markers from the same specific cell type are shown in Table I.

**TABLE I**

<b>MARKER</b>	<b>SIZE (D)</b>	<b>SMALLEST FRAGMENT (D)</b>
<b>SPECIFIC GLIAL MARKERS:</b>		
S100	21,000	10,500
Growth Associated Protein 43 (GAP-43)	43,000	43,000
Glutamine Synthetase (GS)	400,000	44,000
Glial Fibrillary Acid Protein (GFAP)	51,000	51,000
Glycine Transporter (GLYT1)	50-70,000	50-70,000
Glycine Transporter (GLYT2)	90-110,000	90-110,000
<b>SPECIFIC NEURONAL MARKERS:</b>		
Neuron Specific Enolase (NSE)	78,000	39,000
Neuron Specific Glycoprotein (GP50)	42,000	42,000
Calpain	80,000	55,000
Neurofibrillary Protein (NF)	68,000	68,000
Heat Shock Protein 72 (HSP-72)	72,000	72,000
Beta Amyloid Precursor Protein (beta APP)	250,000	125,000
<b>SPECIFIC AXONAL MARKERS:</b>		
Myelin Basic Protein (MBP)	18,500	18,500
Calbindin D-28K	28,000	28,000
Proteolipid Protein (PLP)	23-30,000	23-30,000
Myelin Associated Glycoprotein (MAG)	90-100,000	58,000
Neurofilament H (HFN)	200,000	200,000

In a preferred embodiment of the invention body fluid samples taken from a patient at different points in time are analyzed. Typically a first body fluid sample is taken from a patient upon presentation with symptoms of stroke and analyzed according to the invention. Subsequently, some period of time after presentation, for example, about two hours after presentation, a second body fluid sample is taken and analyzed according to the invention. Referring now to Fig. 2 there is seen a flow chart illustrating how the data obtained from four marker proteins analyzed according to the invention, in the embodiment illustrated NSE, S100, MBP and Tm, can be used to triage the patient. The data can be used to diagnose stroke, rule out stroke,

distinguish between thrombotic and hemorrhagic stroke, identify appropriate patients for thrombolytic treatment and determine how the stroke is evolving.

As stated previously, the level of each of the four specific markers in the patient's body fluid can be measured from one single sample or one or more individual markers can be measured in one sample and at least one marker measured in one or more additional samples. By "sample" is meant a volume of body fluid such as blood or CSF which is obtained at one point in time. Further, as will be discussed in detail below, all the markers can be measured with one assay device or by using a separate assay device for each marker in which case aliquots of the same fluid sample 5 can be used or different fluid samples can be used. It is apparent that the analyses should be carried out within some short time frame after the sample is taken, e.g., within about one-half hour, so the data can be used to prescribe treatment as quickly as possible. It is preferred to measure each of the four markers in the same single sample, irrespective of whether the analyses are carried out in a single analytical 10 device or in separate such devices so the level of each marker simultaneously present 15 in a single sample can be used to provide meaningful data.

Generally speaking, the presence of each marker is determined using antibodies specific for each of the markers and detecting immunospecific binding of each antibody to its respective cognate marker. Any suitable immunoassay method 20 may be utilized, including those which are commercially available, to determine the level of each of the specific markers measured according to the invention. Extensive discussion of the known immunoassay techniques is not required here since these are known to those of skill in the art. Typical suitable immunoassay techniques include sandwich enzyme-linked immunoassays (ELISA), radioimmunoassays (RIA), 25 competitive binding assays, homogeneous assays, heterogeneous assays, etc. Various of the known immunoassay methods are reviewed in Methods in Enzymology, 70, pp. 30-70 and 166-198 (1980). Direct and indirect labels can be used in immunoassays. A direct label can be defined as an entity, which in its natural state, is visible either to the naked eye or with the aid of an optical filter and/or applied stimulation, e.g., 30 ultraviolet light, to promote fluorescence. Examples of colored labels which can be used include metallic sol particles, gold sol particles, dye sol particles, dyed latex

particles or dyes encapsulated in liposomes. Other direct labels include radionuclides and fluorescent or luminescent moieties. Indirect labels such as enzymes can also be used according to the invention. Various enzymes are known for use as labels such as, for example, alkaline phosphatase, horseradish peroxidase, lysozyme, glucose-6-phosphate dehydrogenase, lactate dehydrogenase and urease. For a detailed discussion of enzymes in immunoassays see Engvall, Enzyme Immunoassay ELISA and EMIT, Methods of Enzymology, 70, 419-439 (1980).

A preferred immunoassay method for use according to the invention is a double antibody technique for measuring the level of the marker proteins in the patient's body fluid. According to this method one of the antibodies is a "capture" antibody and the other is a "detector" antibody. The capture antibody is immobilized on a solid support which may be any of various types which are known in the art such as, for example, microtiter plate wells, beads, tubes and porous materials such as nylon, glass fibers and other polymeric materials. In this method, a solid support, e.g., microtiter plate wells, coated with a capture antibody, preferably monoclonal, raised against the particular marker protein of interest, constitutes the solid phase. Diluted patient body fluid, e.g., serum or plasma, typically about 25 µl, standards and controls are added to separate solid supports and incubated. When the marker protein is present in the body fluid it is captured by the immobilized antibody which is specific for the protein. After incubation and washing, an anti-marker protein detector antibody, e.g., a polyclonal rabbit anti-marker protein antibody, is added to the solid support. The detector antibody binds to marker protein bound to the capture antibody to form a sandwich structure. After incubation and washing an anti-IgG antibody, e.g., a polyclonal goat anti-rabbit IgG antibody, labeled with an enzyme such as horseradish peroxidase (HRP) is added to the solid support. After incubation and washing a substrate for the enzyme is added to the solid support followed by incubation and the addition of an acid solution to stop the enzymatic reaction.

The degree of enzymatic activity of immobilized enzyme is determined by measuring the optical density of the oxidized enzymatic product on the solid support at the appropriate wavelength, e.g., 450 nm for HRP. The absorbance at the wavelength is proportional to the amount of marker protein in the fluid sample. A set

of marker protein standards is used to prepare a standard curve of absorbance vs. marker protein concentration. This method is preferred since test results can be provided in 45 to 50 minutes and the method is both sensitive over the concentration range of interest for each marker and is highly specific.

5       The assay methods used to measure the marker proteins should exhibit sufficient sensitivity to be able to measure each protein over a concentration range from normal values found in healthy persons to elevated levels, i.e., 2SD above normal and beyond. Of course, a normal value range of the marker proteins can be found by analyzing the body fluid of healthy persons. For the S100b isoform where  
10       $+2SD = 0.02 \text{ ng/mL}$  the upper limit of the assay range is preferably about 5.0 ng/mL. For NSE where  $+2SD = 9.9 \text{ ng/mL}$  the upper limit of the range is preferably about 60 ng/mL. For MBP, which has an elevated level cutoff value of 0.02 ng/mL, the upper limit of the assay range is preferably about 5.0 ng/mL and for Tm, which has an elevated level cutoff value of about 73 ng/mL, the assay range upper limit is  
15      preferably about 500 ng/mL.

The assays can be carried out in various assay device formats including those described in United States Patents 4,906,439; 5,051,237 and 5,147,609 to PB Diagnostic Systems, Inc.

20       The assay devices used according to the invention can be arranged to provide a semiquantitative or a quantitative result. By the term "semiquantitative" is meant the ability to discriminate between a level which is above the elevated marker protein value, and a level which is not above that threshold.

25       The assays may be carried out in various formats including, as discussed previously, a microtiter plate format which is preferred for carrying out the assays in a batch mode. The assays may also be carried out in automated immunoassay analyzers which are well known in the art and which can carry out assays on a number of different samples. These automated analyzers include continuous/random access types. Examples of such systems are described in United States Patents 5,207,987 and 5,518,688 to PB Diagnostic Systems, Inc. Various automated analyzers that are  
30      commercially available include the OPUS® and OPUS MAGNUM® analyzers.

Another assay format which can be used according to the invention is a rapid manual test which can be administered at the point-of-care at any location. Typically, such point-of-care assay devices will provide a result which is above or below a threshold value, i.e., a semiquantitative result as described previously.

5 It should be recognized also that the assay devices used according to the invention can be provided to carry out one single assay for a particular marker protein or to carry out a plurality of assays, from a single volume of body fluid, for a corresponding number of different marker proteins. A preferred assay device of the latter type is one which can provide a semiquantitative result for the four primary 10 marker proteins measured according to the invention, i.e., S100b, NSE, MBP and a brain endothelial marker protein, e.g., Tm. These device typically are adapted to provide a distinct visually detectable colored band at the location where the capture antibody for the particular marker protein is located when the concentration of the marker protein is above the threshold level. For a detailed discussion of assay types 15 which can be utilized according to the invention as well as various assay formats and automated analyzer apparatus see U.S. Patent 5,747,274 to Jackowski.

The invention will now be described further in detail with respect to specific preferred embodiments, it being understood that these are intended to be illustrative only and the invention is not limited to the materials, procedures, etc. recited therein.

20

#### EXAMPLE

A prospective observational pilot study was carried out at two tertiary care hospitals. The study evaluated thirty three patients admitted with a clinical and computed tomographic (CT) diagnosis of acute ischemic stroke. The mean age of the patients presenting with stroke was approximately 66 years ( $66.4 \pm 16.4$ ) with an age 25 range of from 27 to 90 years. The mean delay between the onset of symptoms and presentation to the hospital was 22 hours with a range of from 1 to 72 hours. Admission National Institutes of Health Stroke Scale and Discharge modified Rankin scale scores were recorded. Blood samples were obtained on days 1 (presentation), 3, 5 and 7 at one hospital and days 1, 2 and 3 at the second hospital. All blood samples

were centrifuged and aliquots of serum were frozen and stored at -80°C until analysis for S100, NSE, MBP and Tm.

Control subjects included one hundred three healthy blood donors (age range from 18 to 78 years; mean age  $54.6 \pm 15.2$  years) whose blood samples were used to 5 determine reference values for concentrations of S100 and NSE and twenty four healthy blood donors who provided samples for reference measurements of MBP and Tm concentrations.

All reference values are reported as mean +2SD unless otherwise stated. The reference value for S100 in serum was 0.0067 ng/mL with a 98th percentile of 0.020 10 ng/mL. An elevated S100 value was taken as any concentration greater than the 98th percentile (0.02 ng/mL) of normal (normal +2SD = 0.02 ng/mL).

The reference value for NSE in serum was  $5.03 \pm 2.40$  ng/mL. An elevated NSE value was any concentration greater than 2SD above normal, 9.85 ng/mL.

The reference value for MBP in serum was  $0.0162 \pm 0.0019$  ng/mL. An elevated MBP value was any concentration greater than 2SD above normal, 0.02 15 ng/mL.

The reference value for Tm in serum was  $50.52 \pm 13.62$  ng/mL. An elevated Tm value was any concentration greater than +2SD above normal, 76.14 ng/mL.

The levels of S100 and NSE were analyzed using Exact S100 and Exact NSE 20 Elisa Assay Kits, respectively, available from Skye PharmaTech Inc., Mississauga, Canada. The levels of Tm were analyzed with an ELISA assay available from Diagnostica Stago, 9 rue des Freres Chausson, 92600 Asneres Sur Seine, France. The level of MBP concentration was analyzed with an ELISA immunoassay from Diagnostic Systems Laboratories, Webster, Texas, United States.

In the tables showing the data obtained "D1" indicates the first day with the 25 first blood sample being taken at the time of presentation. Subsequent days of sample collection are indicated by D2, D3, etc. For the values of the concentrations of the markers, +2SD are above the normal range. "ND" signifies that no data was obtained.

**TABLE II**  
**NSE, S100, MBP ND Tm CONCENTRATIONS IN**  
**CLINICAL SERUM SAMPLES**

CODE #	AGE	GENDER	NSE (ng/mL) + 2SD=9.9	S100 (ng/mL) + 2SD=0.02	MBP (ng/mL) + 2SD=0.02	Tm (ng/mL) + 2SD=73
SM-1 D1	42	Female	8.342	0.028	0.000	43.535
SM-1 D3			13.300	1.098	ND	61.946
SM-1 D5			9.622	0.060	0.238	65.859
SM-1 D7			10.710	0.066	1.725	62.177
<b>DIAGNOSIS</b>	Left internal carotid. CEREBRAL INFARCT (arteroembolic). 5h from onset of symptoms.					
<b>OUTCOME</b>	GOOD. Mild aphasia.					
SM-2 D1	55	Female	9.420	0.053	0.032	ND
SM-2 D3			5.430	0.015	0.105	ND
SM-2 D5			7.360	0.011	0.341	ND
SM-2 D7			9.906	0.008	0.124	ND
<b>DIAGNOSIS</b>	CEREBRAL INFARCT. Posterior circulation infarction (unknown mechanism). 20 h from onset of symptoms.					
<b>OUTCOME</b>	MODERATE. Dysarthria and hemiparesis.					
SM-3 D1	78	Male	12.670	0.112	0.000	92.324
SM-3 D3			14.980	0.719	1.420	101.990
SM-3 D5			28.570	1.301	4.845	119.251
<b>DIAGNOSIS</b>	CEREBRAL INFARCT. Total anterior circulation infarction (cardioembolic).					
<b>OUTCOME</b>	DEATH					
SM-4 D1	58	Male	8.520	0.008	0.000	73.913
SM-4 D3			4.406	0.028	0.147	78.286
SM-4 D5			4.888	0.024	0.265	85.881
<b>DIAGNOSIS</b>	CEREBRAL INFARCT. Lacunar circulation infarction (lacune).					
<b>OUTCOME</b>	GOOD. Mild ataxic hemiparesis.					

**TABLE II**  
**NSE, S100, MBP ND Tm CONCENTRATIONS IN**  
**CLINICAL SERUM SAMPLES**

CODE #	AGE	GENDER	NSE (ng/mL) + 2SD=9.9	S100 (ng/mL) + 2SD=0.02	MBP (ng/mL) + 2SD=0.02	Tm (ng/mL) + 2SD=73
SM-5 D2	27	Male	9.139	0.099	2.301	59.415
SM-5 D3			5.492	0.000	0.090	53.892
SM-5 D5			11.730	0.079	7.682	68.850
SM-5 D7			11.540	0.018	10.382	68.620
<b>DIAGNOSIS</b>	CEREBRAL INFARCT (fibromuscular dysplasia). 48h from onset of symptoms.					
<b>OUTCOME</b>	MODERATE. Aphasia and hemiparesis.					
SM-6 D1	63	Male	7.029	0.000	0.000	56.883
SM-6 D3			6.455	0.020	0.000	75.985
<b>DIAGNOSIS</b>	CEREBRAL INFARCT (unknown mechanism). 22 h from onset of symptoms.					
<b>OUTCOME</b>	MODERATE					
SM-7 D1	64	Female	8.566	0.021	0.013	105.212
SM-7 D3			5.061	0.024	0.000	129.146
SM-7 D5			6.783	0.021	0.017	129.607
SM-7 D8			7.377	0.015	0.000	162.746
<b>DIAGNOSIS</b>	CEREBRAL INFARCT. Lacunar circulation infarction (lacune).					
<b>OUTCOME</b>	MODERATE. Hemiparetic.					
SM-8 D1	45	Male	15.740	0.053	0.009	37.092
SM-8 D3			21.010	0.112	0.082	35.711
DM-8 D5			15.060	0.095	0.112	38.703
<b>DIAGNOSIS</b>	CEREBRAL INFARCT (Right vertebral dissection).					
<b>OUTCOME</b>	GOOD. Minimal deficit.					

**TABLE II**  
**NSE, S100, MBP ND Tm CONCENTRATIONS IN**  
**CLINICAL SERUM SAMPLES**

CODE #	AGE	GENDER	NSE (ng/mL) + 2SD=9.9	S100 (ng/mL) + 2SD=0.02	MBP (ng/mL) + 2SD=0.02	Tm (ng/mL) + 2SD=73
SM-9 D1	35	Male	11.530	0.015	0.101	ND
SM-9 D5			8.033	0.021	0.040	ND
SM-9 D7			7.336	0.002	0.000	ND
<b>DIAGNOSIS</b>	CEREBRAL INFARCT (unknown mechanism).					
<b>OUTCOME</b>	GOOD. Minimal deficit.					

**TABLE III**

CODE #	AGE	GENDER	NSE (ng/mL) + 2SD=9.9	S100 (ng/mL) + 2SD=0.02	MBP (ng/mL) + 2SD=0.02	Tm (ng/mL) + 2SD=73
SJ-01 D1	83	MALE	6.803	0.091	0.000	185.760
SJ-01 D2			8.566	0.235	0.000	166.659
SJ-01 D3			8.689	1.143	0.000	209.234
<b>DIAGNOSIS</b>	CEREBRAL INFARCT (recurrent). ↑BP, renal insufficiency, MI					
<b>OUTCOME</b>	Severe impairment developed on second day.					
SJ-02 D1	61	MALE	14.040	0.054	0.433	476.193
SJ-02 D2			13.430	0.110	1.199	403.010
SJ-02 D3			12.890	0.247	2.625	501.739
<b>DIAGNOSIS</b>	CEREBRAL INFARCT (parietal infarction), renal failure, MI, CA. 48 h from onset of symptoms					
<b>OUTCOME</b>	First CT negative. Second CT positive (Day 3). DEATH (day 5)					
SJ-03 D1	83	MALE	10.700	0.000	0.000	75.064
SJ-03 D2			8.926	0.000	0.000	81.968
SJ-03 D3			9.000	0.000	0.000	89.793
<b>DIAGNOSIS</b>	CEREBRAL INFARCT (lacune). ↑ BP, DM					
<b>OUTCOME</b>	CT positive (Day 2)					

TABLE III

CODE #	AGE	GENDER	NSE (ng/mL) + 2SD=9.9	S100 (ng/mL) + 2SD=0.02	MBP (ng/mL) + 2SD=0.02	Tm (ng/mL) + 2SD=73
SJ-04 D1	70	FEMALE	10.270	0.000	0.000	134.209
DIAGNOSIS	TIA. ↑BP, DM					
OUTCOME						
SJ-05 D1	72	MALE	6.639	0.000	0.326	185.760
SJ-05 D2			10.870	0.000	0.219	136.281
SJ-05 D3			8.197	0.000	0.387	132.598
DIAGNOSIS	CEREBRAL INFARCT (lacune), renal impairment					
OUTCOME	First CT negative					
SJ-06 D1	81	FEMALE	10.440	0.001	0.086	ND
DIAGNOSIS	CEREBRAL INFARCT. Renal impairment (dialysis). 36 h from onset of symptoms					
OUTCOME						
SJ-07 D1	90	FEMALE	12.540	0.001	0.162	ND
DIAGNOSIS	CEREBRAL INFARCT. 36 h from onset of symptoms					
OUTCOME						
SJ-08 D1	81	MALE	12.450	0.749	0.017	82.198
DIAGNOSIS	HAEMORRHAGIC. 1 h from onset of symptoms					
OUTCOME	CT positive. DEATH 2 h later.					
SJ-09 D1	46	MALE	4.891	0.000	0.000	88.182
SJ-09 D2			3.913	0.000	0.000	87.722
SJ-09 D3			1.848	0.000	0.000	105.903
DIAGNOSIS	STROKE (clinically). PA within 3 h of onset of symptoms					
OUTCOME	CT negative					

**TABLE III**

CODE #	AGE	GENDER	NSE (ng/mL) + 2SD=9.9	S100 (ng/mL) + 2SD=0.02	MBP (ng/mL) + 2SD=0.02	Tm (ng/mL) + 2SD=73
SJ-10 D1	69	FEMALE	8.303	0.000	0.000	79.437
SJ-10 D2			6.000	0.000	0.000	74.144
SJ-10 D3			3.939	0.000	0.000	68.850
<b>DIAGNOSIS</b>	~12 h from onset of symptoms - numbness in arms - R side facial droop; difficulty swallowing - no past Hx CVA - patient diabetic; has Hx high BP					
<b>OUTCOME</b>	Initial CT negative. All symptoms resolved; except patient still unable to swallow.					
SJ-11 D1	39	MALE	10.770	0.058	0.063	65.398
SJ-11 D2			12.050	0.047	0.128	69.311
SJ-11 D3			17.330	0.068	0.189	76.675
<b>DIAGNOSIS</b>	CEREBRAL INFARCT. ~24 h from onset of symptoms - found unconscious with R-sided neglect					
<b>OUTCOME</b>	CT positive (Day 1) - 3 lesions present ~2 cm - basal ganglia L side Patient still has severe weakness R side with speech impairment					
SJ-12 D1	51	FEMALE	11.700	0.000	0.067	286.100
SJ-12 D2			8.788	0.000	0.055	270.911
SJ-12 D3			11.800	0.002	0.124	226.264
<b>DIAGNOSIS</b>	CEREBRAL INFARCT (lacune). ~ 12 h from onset of symptoms - weakness L side, esp. L arm - facial droop and pronounced slurring of speech - Bell's Palsy L side - renal dialysis patient					
<b>OUTCOME</b>	CT positive (Day 1) - developed thrombocytopenia Day 2					

TABLE III

CODE #	AGE	GENDER	NSE (ng/mL) + 2SD=9.9	S100 (ng/mL) + 2SD=0.02	MBP (ng/mL) + 2SD=0.02	Tm (ng/mL) + 2SD=73
SJ-13 D1	78	FEMALE	10.090	0.000	0.000	46.297
SJ-13 D2 (Haemolytic)			40.040	0.768	0.433	41.924
SJ-13 D3			4.667	0.103	0.000	36.861
<b>DIAGNOSIS</b>	CEREBRAL INFARCT (Left MCA CVA) + CAD, + Diabetic, Hx HTN, + family Hx CVA. ~ 19 h from onset of symptoms					
<b>OUTCOME</b>	Initial CT negative. Initial symptoms worsened over 48 h to R hemiplegia.					
SJ-14 D1	72	MALE	7.303	0.087	0.299	NC
SJ-14 D2			5.697	0.007	0.055	NC
<b>DIAGNOSIS</b>	CEREBRAL INFARCT (Left CVA). ~ 9 h from onset of symptoms - prior CVA 1989 - Hx strial fib., anticoagulated - MI 1997					
<b>OUTCOME</b>	Symptoms improving					
SJ-15 D1	79	MALE	5.667	0.000	0.013	ND
<b>DIAGNOSIS</b>	CEREBRAL INFARCT (Left CVA) - symptoms progressive over 2 wk period; worsened over 3 day period just prior to presentation at hospital.					
<b>OUTCOME</b>	CT negative Day 1 - condition worsening at discharge (discharged at family's request for palliative care at home)					
SJ-16 D1	90	FEMALE	20.940	0.811	5.142	52.281
SJ-16 D2			12.220	0.498	5.459	55.733
SJ-16 D3			9.424	0.253	3.377	55.503
<b>DIAGNOSIS</b>	Large intracerebral bleed with smaller subdural hematoma and intraventricular hemorrhage - Onset of symptoms unknown (6 to 29 h prior) - previously well; no Hx other than colon Ca 20 yr prior; on no meds at home; found collapsed					
<b>OUTCOME</b>	Patient continues to worsen					

TABLE III

CODE #	AGE	GENDER	NSE (ng/mL) + 2SD=9.9	S100 (ng/mL) + 2SD=0.02	MBP (ng/mL) + 2SD=0.02	Tm (ng/mL) + 2SD=73
SJ-17 D1	77	MALE	10.660	0.042	0.002	ND
SJ-17 D2			8.758	0.095	0.006	ND
SJ-17 D3			12.510	0.261	0.417	ND
DIAGNOSIS	CEREBRAL INFARCT (Right CVA) - old left cerebellar infarct - sudden onset; slurred speech and L-sided weakness ~ 15 h from onset of symptoms					
OUTCOME	CT showed old CVA and new right MCA infarct					
SJ-18 D1	79	MALE	21.560	0.008	0.000	61.946
SJ-18 D2			14.390	0.218	0.814	48.598
SJ-18 D3			11.050	0.102	0.698	55.963
DIAGNOSIS	Initial CT showed bleed or cerebral edema. ~ 2 h from onset of symptoms					
OUTCOME	Aphasia and R-sided weakness					
SJ-19 D1	82	FEMALE	9.948	0.000	ND	64.248
SJ-19 D2			9.781	0.008	ND	58.955
SJ-19 D3			11.720	0.023	ND	64.248
DIAGNOSIS	TIA ~ 24 h from onset of symptoms					
OUTCOME	Slurred speech, difficulty swallowing which persists.					
SJ-20 D1	ND	MALE	26.400	0.122	0.000	32.719
DIAGNOSIS	Haemorrhagic stroke					
OUTCOME						
SJ-21 D1	74	MALE	5.828	0.016	ND	74.374
SJ-21 D2			7.423	0.063	ND	75.985
SJ-21 D3			8.436	0.286	ND	71.382
DIAGNOSIS	CEREBRAL INFARCT (left CVA)					
OUTCOME	R-sided weakness					

TABLE III

CODE #	AGE	GENDER	NSE (ng/mL) + 2SD=9.9	S100 (ng/mL) + 2SD=0.02	MBP (ng/mL) + 2SD=0.02	Tm (ng/mL) + 2SD=73
SJ-22 D1 (Haemolytic)	63	FEMALE	18.600	0.000	0.000	ND
SJ-22 D2			9.540	0.008	0.000	ND
DIAGNOSIS	CEREBRAL INFARCT (left CVA), initial CT negative					
OUTCOME	weakness (resolving)					
SJ-23 D1	79	MALE	14.530	2.009	5.478	ND
SJ-23 D2			23.980	>3.200	8.155	ND
SJ-23 D3			27.670	2.218	7.309	ND
DIAGNOSIS	CEREBRAL INFARCT, CT positive					
OUTCOME	CT showed multiple cerebral infarcts.					
SJ-24 D1	73	MALE	20.630	0.000	0.000	74.160
SJ-24 D2			17.880	0.000	0.000	89.750
SJ-24 D3			17.880	0.000	0.000	83.290
DIAGNOSIS	TIA - sudden decrease in ability to function, word difficulties					
OUTCOME	CT negative - Discharged with diagnosis of TIA					

The analysis of S100, NSE and MBP levels in serum samples from healthy control subjects showed no relationship of levels of these proteins to age or sex. In the case of Tm, the concentrations were higher in serum samples from healthy males than in females ( $54.62 \pm 13.62$  ng/mL, 2SD above normal = 81.86 ng/mL and  $43.63 \pm 11.18$  ng/mL, 2SD above normal = 68.74 ng/mL, respectively).

Of the thirty three stroke patients twenty six were infarcts (79%) and of these five were lacunar (15%) and four had hemorrhagic stroke (12%). Of the hemorrhagic stroke patients three had subarachnoid hemorrhage and one had an intracerebral bleed. Three patients (9%) had transient ischemic attacks (TIA).

On presentation the levels of S100 were elevated in 44% of the patients, NSE levels were elevated in 59%, MBP levels were elevated in 40% and Tm levels were elevated in 57%.

The data indicate that by measuring the four marker proteins in accordance  
5 with the invention, where any one marker was elevated, 94% of the patients could be identified on presentation. Nineteen of the twenty one non-lacunar infarcts (90%) could be identified on presentation. The remaining two patients arrived at the hospital at 22 and 72 hours respectively after onset of symptoms.

Each of Figs. 3-10 is a graphical illustration of the data obtained from a  
10 different patient of the study. The concentration levels are expressed as multiples of a reference value and were obtained by dividing the actual measured concentration values by the defined reference value for each respective marker protein, i.e., the 2SD value.

All lacunar infarcts, hemorrhagic and TIA patients were identified on  
15 presentation with 100% accuracy. All five lacunar infarcts had elevated levels of Tm on presentation. In some patients the only elevated marker protein was Tm. Referring now to Fig. 3 it can be seen that, for patient SM7, the only elevated marker protein was Tm indicating a lacunar infarct.

The three TIA patients had elevated NSE levels and normal S100 and MBP  
20 levels that stayed within the normal range. Tm was elevated in one of the TIA patients. Referring now to Fig. 4 it can be seen that for patient SM-24, Tm was slightly elevated and NSE was elevated indicating a TIA. The patient was discharged with diagnosis of TIA. Referring now to Fig. 5 it can be seen that patient SM-3 had greatly elevated levels of MBP and S100 as well as elevated levels of NSE and Tm  
25 indicating a cerebral infarct with damage spreading into the base of the brain.

In the four hemorrhagic stroke patients, the three subarachnoid hemorrhagic patients had elevated levels of S100 and NSE and a normal Tm level. In the patient with an intracerebral hemorrhagic stroke the levels of S100 and NSE were elevated and the level of MBP was elevated about 250 times. Fig. 6 illustrates that patient SJ-  
30 16 had a 250 fold increased level of MBP upon presentation as well as elevated levels of S100 and NSE and had suffered an intracerebral hemorrhage.

Fig. 7 illustrates that patient SJ-2 had elevated MBP, Tm and S100 upon presentation and that the MBP and S100 levels continued to increase with time indicating a cerebral infarct with the stroke increasing over time. An initial CAT scan upon presentation was negative and became positive only days later.

5 Fig. 8 illustrates that patient SJ-18 presented with a TIA which evolved into a stroke. Tm was in the normal range indicating that the cerebral vasculature was not compromised and thus indicating that the patient was a good candidate for thrombolysis.

10 Fig. 9 illustrates that patient SM-8 presented with a cerebral infarct and, with Tm in the normal range, was a good candidate for thrombolysis since the endothelial vasculature was not compromised.

Fig. 10 illustrates that patient SJ-1 had a cerebral infarct and because of the elevated Tm level was at risk of hemorrhage if given thrombolytics because of the endothelial vasculature being compromised.

15 For the second serum sample obtained the levels of S100 were elevated in 73% of the stroke patients, the NSE levels in 54%, MBP levels in 64% and Tm levels in 55%. These data indicated that by measuring the four marker proteins in accordance with the invention, where any one marker was elevated 96% of the patients could be identified from the second serum sample obtained.

20 The data indicate that the levels of the protein markers in subsequent serum samples either increased or decreased depending upon whether the stroke was evolving in severity or subsiding.

25 Eighteen (54%) of the thirty three stroke patients had a CAT scan performed on presentation. All four hemorrhagic stroke patients were CAT positive at presentation. Nine (50%) of the eighteen patients had a normal CAT at presentation which became positive days later. Eight of these nine patients who had a normal CAT on presentation had elevated levels of one or more of the four protein markers on presentation. All of the nine CAT positive patients on presentation also had elevated levels of one or more protein markers on presentation.

Peak S100, NSE and MBP levels were significantly correlated (Pearson's) with admission NIHSS scores ( $p < 0.05$ ) and discharge modified Rankin scores ( $p < 0.05$ ).

The data show that levels of S100, NSE, MBP and Tm can be easily and  
5 reliably measured in acute ischemic stroke patients and that by measuring these four  
marker proteins in accordance with the invention, when any one marker protein is  
elevated a 94% sensitivity for acute ischemic stroke can be achieved upon  
presentation. Further, in the hyperacute period of the evolving stroke, elevated levels  
of one or more of these four marker proteins appear to precede irreversible tissue  
10 damage and brain edema prior to detection of such damage by CAT.

Although the invention has been described with respect to various preferred  
embodiments it is not intended to be limited thereto but rather those skilled in the art  
will recognize that variations and modifications may be made therein which are  
within the spirit of the invention and the scope of the appended claims.

## CLAIMS:

1. A method for diagnosing and distinguishing stroke comprising
  - a. analyzing the body fluid of a patient to detect the presence and concentration of four markers of stroke wherein
    - i. A first marker is myelin basic protein,
    - ii. a second marker is the beta isoform of S100 protein,
    - iii. a third marker is neuronal specific enolase,
    - iv. a fourth marker is a brain endothelial cell membrane protein
  - and
  - b. from the information obtained from said analyses verifying whether an ischemic or hemorrhagic cerebral event has occurred and differentiating a particular type of cerebral event.
2. A method as defined in claim 1 wherein said body fluid is selected from the group consisting of blood, blood products and cerebrospinal fluid.
3. A method as defined in claim 1 wherein each of said analyses is carried out on the same sample of body fluid.
4. A method as defined in claim 1 wherein at least one of said analyses is carried out on a first sample of body fluid and at least another of said analyses is carried out on a second sample of body fluid.
5. A method as defined in claim 4 wherein said first and said second samples of body fluid are taken at different time periods.
6. A method as defined in claim 1 wherein said brain endothelial cell membrane protein is selected from the group consisting of Thrombomodulin, Glucose Transporter 1 in the dimeric or tetrameric form, Neurothelin/HT7, Gamma Glutamyl Transpeptidase, P-glycoprotein and combinations thereof.

7. A method as defined in claim 1 wherein at least one of said analyses comprises contacting said body fluid with an antibody which is specific for said marker.

8. A method as defined in claim 7 wherein at least one of said analyses is carried out with an enzyme-labeled immunoassay method.

9. A method as defined in claim 1 and further including the step of analyzing said body fluid for a fifth marker protein, wherein said fifth marker protein has the same specific cell type as one of said first, second or third markers and has a higher molecular weight than said first, second or third marker which has the same specific cell type.  
5

10. A method as defined in claim 9 wherein at least one of said analyses comprises contacting said body fluid with an antibody which is specific for said marker.

11. A method as defined in claim 10 wherein at least one of said analyses is carried out with an enzyme-labeled immunoassay method.

12. A method as defined in claim 1 and further including the step of analyzing a second sample of a body fluid from said patient for said four markers, said second sample of body fluid being taken at a time subsequent to said body fluid analyzed in step a.

13. A method as defined in claim 1 wherein said steps of verifying and differentiating include comparing the concentration level detected in said analysis for each said four markers to a predefined threshold level for each said marker.

14. A diagnostic kit for diagnosing and distinguishing stroke comprising at least four antibodies which are specific for each of four different marker proteins, said antibodies immobilized on a solid support, wherein

10 a. a first marker protein is myelin basic protein and a first antibody is specific therefor,

b. a second marker protein is the beta isoform of S100 protein and a second antibody is specific therefor,

15 c. a third marker protein is neuronal specific enolase and a third antibody is specific therefor, and

d. a fourth marker protein is a brain endothelial cell membrane protein and a fourth antibody is specific therefor and at least four labeled antibodies, each of said labeled antibodies binding to one of said marker proteins.

15. A diagnostic kit as defined in claim 14 wherein each of said four antibodies is immobilized on the same solid support.

16. A diagnostic kit as defined in claim 14 wherein at least one of said four antibodies is immobilized on a first solid support and at least another of said four antibodies is immobilized on a second solid support.

17. A diagnostic kit as defined in claim 14 wherein at least one of said labeled antibodies comprises an enzyme-labeled antibody.

18. A diagnostic kit as defined in claim 14 wherein said brain endothelial cell marker protein is selected from the group consisting of Thrombomodulin, Glucose Transporter 1 in the dimeric or tetrameric form, Neurothelin/HT7, Gamma Glutamyl Transpeptidase, P-glycoprotein and combinations thereof.

19. A diagnostic kit as defined in claim 14 and further including a fifth antibody which is specific for a fifth marker protein, wherein said fifth marker protein has the same specific cell type as one of said first, second or third markers and has a higher molecular weight than said first, second or third marker which has the same

5 specific cell type, and a fifth labeled antibody which binds to said fifth marker protein.

20. A diagnostic kit as defined in claim 19 wherein said fifth labeled antibody comprises an enzyme-labeled antibody.

21. A method for the differential diagnosis of ischemic and hemorrhagic 5 cerebral events comprising

a. analyzing the body fluid of a patient to detect the presence and concentration level of one or more ischemic marker proteins selected from the group consisting of myelin basic protein, the beta isoform of S100 protein, neuronal specific enolase and combinations thereof,

10 b. analyzing the body fluid of said patient to detect the presence and concentration level of a brain endothelial cell membrane protein, and

c. from the information obtained from said analyses, verifying the occurrence of an ischemic or hemorrhagic cerebral event and differentiating a particular type of cerebral event.

15 22. A method as defined in claim 21 wherein said steps of verifying and differentiating include comparing the concentration levels detected in said analyses for said one or more ischemic marker proteins and for said brain endothelial cell membrane protein to a predefined threshold level for each said ischemic marker protein and for said brain endothelial cell membrane protein.

20 23. A method as defined in claim 21 wherein said body fluid is selected from the group consisting of blood, blood products and cerebrospinal fluid.

24. A method as defined in claim 21 wherein said brain endothelial cell membrane protein is selected from the group consisting of Thrombomodulin, Glucose Transporter 1 in the dimeric or tetrameric form, Neurothelin/HT7, Gamma Glutamyl 25 Transpeptidase, P-glycoprotein and combinations thereof.

25. A method as defined in claim 24 wherein said brain endothelial cell membrane protein is Thrombomodulin.

26. A method as defined in claim 21 further including  
30       analyzing said body fluid to detect the presence and concentration level of a secondary marker protein having the same specific cell type as one of said myelin basic protein, beta isoform of S100 protein or neuronal specific enolase whereby the time of onset of a hemorrhagic or ischemic cerebral event can be determined.

27. A method as defined in claim 26 wherein said secondary marker protein  
35       has a higher molecular weight than said myelin basic protein, beta isoform of S100 protein or neuronal which has the same specific cell type.

28. A method as defined in claim 21 wherein each of said analyses is carried on the same sample of body fluid.

29. A method as defined in claim 21 wherein at least one of said analyses is  
40       carried out on a first sample of body fluid and at least another of said analyses is carried out on a second sample of body fluid.


30. A method as defined in claim 29 wherein said first and said second samples of body fluid are taken at different time periods.

31. A method as defined in claim 21 wherein  
45       a plurality of samples of said body fluid are obtained at predefined time intervals and analyzed and the information from said analyses compared as a function of time whereby the progression of an ischemic or hemorrhagic cerebral event can be determined.


32. A method as defined in claim 21 wherein each of said analyses comprises  
50       contacting said body fluid with an antibody which is specific for said protein.

33. A method as defined in claim 32 wherein at least one of said analyses is carried out with an enzyme-labeled immunoassay method.



1/6

Fig 1



2/6





3/6





4/6





6/6



**INTERNATIONAL SEARCH REPORT**

Int'l Application No.
PCT/CA 00/00182

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC 7 G01N33/68

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	PERSSON, L. ET AL.: "S-100 Protein and Neuron-Specific Enolase in Cerebrospinal Fluid and Serum: Markers of Cell Damage in Human Central Nervous System" STROKE, vol. 18, 1987, pages 911-918, XP000913410 the whole document	1-33
A	WO 96 32648 A (SPECTRAL DIAGNOSTICS INC) 17 October 1996 (1996-10-17) abstract; figure 12	1-33
A	SU 1 802 337 A (BARSUKOV SERGEJ F ;DMITRASHCHENKO ALEKSEJ A (SU)) 15 March 1993 (1993-03-15) abstract	1-33



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

\* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority, claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

31 May 2000

Date of mailing of the international search report

16/06/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.  
Fax: (+31-70) 340-3016

Authorized officer

Gundlach, B

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 00/00182

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	LAMERS, K.J.B. ET AL.: "Cerebrospinal neuron-specific enolase, S-100 and myelin basic protein in neurological disorders" ACTA NEUROLOGICA SCANDINAVICA, vol. 92, 1995, pages 247-251, XP000910467 page 248, column 1, line 9 -column 2, paragraph 1; tables 1,3 page 250, column 1, paragraph 3 -column 2, paragraph 3 -----	1-33
A	VAN ENGELEN, B.G.M. ET AL.: "Age-Related Changes of Neuron-Specific Enolase, S-100 Protein, and Myelin Basic Protein Concentrations in Cerebrospinal Fluid" CLINICAL CHEMISTRY, vol. 38, no. 6, 1992, pages 813-816, XP000907367 abstract page 815, column 2, paragraph 3 -page 816, column 1 -----	1-33

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CA 00/00182

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9632648 A	17-10-1996	US 5604105 A		18-02-1997
		AU 5117996 A		30-10-1996
		CA 2215018 A		17-10-1996
		EP 0826151 A		04-03-1998
		JP 10511185 T		27-10-1998
		NO 974682 A		10-12-1997
		US 5747274 A		05-05-1998
		US 5744358 A		28-04-1998
		US 5710008 A		20-01-1998
SU 1802337 A	15-03-1993	NONE		